Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,081
  • Shares Outstanding, K 149,531
  • Annual Sales, $ 53,450 K
  • Annual Income, $ -168,840 K
  • 60-Month Beta 2.24
  • Price/Sales 5.83
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.25
  • Number of Estimates 7
  • High Estimate -0.18
  • Low Estimate -0.29
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.76 +6.53%
on 05/31/19
2.23 -15.92%
on 06/18/19
-0.12 (-5.78%)
since 05/24/19
3-Month
1.76 +6.53%
on 05/31/19
3.47 -45.97%
on 05/06/19
-0.54 (-22.20%)
since 03/22/19
52-Week
1.76 +6.53%
on 05/31/19
12.31 -84.77%
on 06/25/18
-10.27 (-84.57%)
since 06/22/18

Most Recent Stories

More News
Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN : 1.87 (-4.59%)
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

CELG : 93.58 (-5.39%)
ADVM : 10.99 (-3.60%)
VRTX : 180.97 (-1.63%)
IMGN : 1.87 (-4.59%)
BIIB : 236.25 (-1.19%)
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

MRK : 85.58 (+1.19%)
IMGN : 1.87 (-4.59%)
RHHBY : 35.3940 (-0.58%)
BSTC : 57.51 (-1.57%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (NASDAQ: IMGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

IMGN : 1.87 (-4.59%)
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin(R) in Ovarian Cancer

--Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease

IMGN : 1.87 (-4.59%)
Look for Shares of Immunogen Inc to Potentially Rebound after Yesterday's 33.78% Sell Off

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $2.09 to a high of $2.20. Yesterday, the shares fell 33.8%, which took the trading range below the 3-day low of $3.07...

IMGN : 1.87 (-4.59%)
ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration...

IMGN : 1.87 (-4.59%)
Report: Developing Opportunities within ImmunoGen, Vulcan Materials, Intuit, and Proofpoint -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ImmunoGen, Inc. (NASDAQ:IMGN),...

INTU : 262.57 (+0.41%)
IMGN : 1.87 (-4.59%)
VMC : 134.46 (-0.34%)
PFPT : 111.70 (-1.19%)
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.

MRK : 85.58 (+1.19%)
IMGN : 1.87 (-4.59%)
EDIT : 21.88 (-4.16%)
RHHBY : 35.3940 (-0.58%)
Biotech Stocks - U.S. Holds On With Largest Medical Device Market Estimated at over $150 Billion

Medical device and technology development is an area where the U.S. companies are at the forefront. According to a SelectUSA.gov publication, the United States remains the largest medical device market...

CELG : 93.58 (-5.39%)
MHMNF : 54.5000 (unch)
IMGN : 1.87 (-4.59%)
VRAY : 8.66 (-0.69%)
ALXN : 127.17 (-3.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade IMGN with:

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 2.17
1st Resistance Point 2.06
Last Price 1.87
1st Support Level 1.87
2nd Support Level 1.79

See More

52-Week High 12.31
Fibonacci 61.8% 8.28
Fibonacci 50% 7.04
Fibonacci 38.2% 5.79
Last Price 1.87
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar